ATE438409T1 - Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen - Google Patents

Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen

Info

Publication number
ATE438409T1
ATE438409T1 AT00402562T AT00402562T ATE438409T1 AT E438409 T1 ATE438409 T1 AT E438409T1 AT 00402562 T AT00402562 T AT 00402562T AT 00402562 T AT00402562 T AT 00402562T AT E438409 T1 ATE438409 T1 AT E438409T1
Authority
AT
Austria
Prior art keywords
expressing cells
cd11b expressing
protein containing
containing vectors
introducing molecules
Prior art date
Application number
AT00402562T
Other languages
English (en)
Inventor
Claude Leclerc
Pierre Guermonprez
Daniel Ladant
Nicole Guiso
Nadia Khelef
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE438409T1 publication Critical patent/ATE438409T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00402562T 2000-09-15 2000-09-15 Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen ATE438409T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00402562A EP1188446B1 (de) 2000-09-15 2000-09-15 Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen

Publications (1)

Publication Number Publication Date
ATE438409T1 true ATE438409T1 (de) 2009-08-15

Family

ID=8173866

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00402562T ATE438409T1 (de) 2000-09-15 2000-09-15 Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen
AT01974315T ATE518880T1 (de) 2000-09-15 2001-09-14 Vektoren zur einführung von molekülen in cd11b exprimierende zellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01974315T ATE518880T1 (de) 2000-09-15 2001-09-14 Vektoren zur einführung von molekülen in cd11b exprimierende zellen

Country Status (17)

Country Link
US (4) US20040001867A1 (de)
EP (2) EP1188446B1 (de)
JP (1) JP2004508065A (de)
KR (2) KR100879151B1 (de)
AT (2) ATE438409T1 (de)
AU (2) AU2001293855B2 (de)
BR (1) BR0113915A (de)
CA (1) CA2422603A1 (de)
CZ (1) CZ2003726A3 (de)
DE (1) DE60042687D1 (de)
ES (1) ES2331348T3 (de)
HK (1) HK1057989A1 (de)
HU (1) HUP0303126A3 (de)
PL (1) PL208864B1 (de)
PT (1) PT1188446E (de)
RU (1) RU2312143C2 (de)
WO (1) WO2002022169A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
EP1188446B1 (de) 2000-09-15 2009-08-05 Institut Pasteur Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen
EP1489092A1 (de) * 2003-06-18 2004-12-22 Institut Pasteur Modifizierte Bordetella Adenylatcyclase mit oder ohne CD11b/CD18 Interaktionsdomäne und seine Verwendungen
JP2008500271A (ja) * 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ
DE602004024440D1 (de) 2003-11-21 2010-01-14 Pasteur Institut Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene
ATE372784T1 (de) * 2004-03-18 2007-09-15 Pasteur Institut Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
EP2242509A1 (de) * 2008-05-29 2010-10-27 Transgene SA Biomarker zur patientenauswahl und entsprechende verfahren
EP2411513B1 (de) * 2009-03-23 2016-11-09 Institut Pasteur Mutierte cyaa-polypeptide und -polypeptidderivate mit eignung zur zuführung immunogener moleküle in eine zelle
EP2233569B1 (de) 2009-03-23 2014-06-25 Institut Pasteur Mutante CyaA-Polypeptide und Polypeptide-Derivate, die zur Lieferung von immunogenen Molekülen in eine Zelle geeignet sind
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
EP2478915A1 (de) 2011-01-24 2012-07-25 Genticel cyaA-getragene Polypeptid(e) und Verwendung zur Induzierung von therapeutischen und prophylaktischen Immunantworten
EP2690172A1 (de) * 2012-07-23 2014-01-29 Genticel CYAA-basierte chimäre Proteine mit einem heterologen Polypeptid und deren Verwendungen bei der Induktion von Immunreaktionen
EP2689786A1 (de) 2012-07-23 2014-01-29 Genticel HPV/CYAA-basierte chimäre Proteine und deren Verwendungen bei der Induktion von Immunreaktionen gegen eine HPV-Infektion und HPV-induzierter Störungen
EP2975120A1 (de) 2014-07-17 2016-01-20 Institut Pasteur Monomeres und funktionelles Adenylatcyclase-CyaA-Toxin
EP3323426A1 (de) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogen- und impfstoffzusammensetzungen zur verwendung gegen bordetella-bronchiseptica-infektion
WO2018091613A1 (en) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3342421A1 (de) 2016-12-27 2018-07-04 Genticel Immunogene zusammensetzung mit cyaa-abgeleitetem polypeptid, das eine th1/th17-orientierte immunreaktion fördert
AU2018413352A1 (en) * 2017-11-03 2020-06-18 Ascendo Biotechnology, Inc. Method for modulation of tumor associated myeloid cells and enhancing immune checkpoint blockade

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
US5182211A (en) 1987-08-07 1993-01-26 Institut Pasteur Plasmid vectors encoding a protein of a picornavirus
US5312902A (en) 1988-06-09 1994-05-17 Institut Pasteur Dimer of the precursor of HIV-2 envelope glycoprotein
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2638169B1 (fr) 1988-10-25 1991-01-11 Pasteur Institut Derives d'adenyl cyclase et leurs utilisations biologiques
ATE123065T1 (de) 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd Proteine und deren herstellung.
NO175188C (no) 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol
US5935580A (en) * 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
ES2290950T3 (es) * 1992-04-21 2008-02-16 Institut Pasteur Mutantes recombinantes para inducir respuestas inmunitarias especificas.
DE69612093T2 (de) * 1995-06-07 2001-10-31 Martin Sevoian Auf antigen verarbeitende zellen zielgerichtete konjugate ein polyaminosäure rückgrat und ein nicht-steroidales antiphlogistikum enthaltend
US5821122A (en) 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
AU2322097A (en) 1996-03-27 1997-10-17 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US6333154B1 (en) * 1997-12-04 2001-12-25 Institut Pasteur Bacterial multi-hybrid system and applications thereof
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
DE60041183D1 (de) * 1999-05-06 2009-02-05 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
KR20020047249A (ko) 1999-10-19 2002-06-21 에드워드 에이. 맥더모트, 주니어 Ｍａｇｅ-ａ12 항원성 펩티드 및 그의 용도
EP1188446B1 (de) 2000-09-15 2009-08-05 Institut Pasteur Proteinhaltigen Vektoren zur Einführung von Moleküle in CD11b exprimirende Zellen
EP1489092A1 (de) 2003-06-18 2004-12-22 Institut Pasteur Modifizierte Bordetella Adenylatcyclase mit oder ohne CD11b/CD18 Interaktionsdomäne und seine Verwendungen
JP2008500271A (ja) 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ
US20070026022A1 (en) 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
DE602004024440D1 (de) 2003-11-21 2010-01-14 Pasteur Institut Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene
ATE372784T1 (de) 2004-03-18 2007-09-15 Pasteur Institut Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.
EP1894941A1 (de) 2006-09-01 2008-03-05 Institut Pasteur Behandlung von Gebärmutterhalskarzinomen mit einer rekombinanten Adenylat-Cyclase die HPV-Antigene trägt
US8017132B2 (en) * 2009-03-23 2011-09-13 Institut Pasteur Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell

Also Published As

Publication number Publication date
HUP0303126A2 (hu) 2003-12-29
DE60042687D1 (de) 2009-09-17
EP1317282A2 (de) 2003-06-11
EP1188446A1 (de) 2002-03-20
ES2331348T3 (es) 2009-12-30
US10004794B2 (en) 2018-06-26
KR100879151B1 (ko) 2009-01-19
BR0113915A (pt) 2003-07-01
CA2422603A1 (en) 2002-03-21
WO2002022169A3 (en) 2002-11-21
HUP0303126A3 (en) 2004-10-28
KR100953364B1 (ko) 2010-04-20
PL365743A1 (en) 2005-01-10
PL208864B1 (pl) 2011-06-30
PT1188446E (pt) 2009-11-10
US20040001867A1 (en) 2004-01-01
HK1057989A1 (en) 2004-04-30
US20160375119A1 (en) 2016-12-29
EP1317282B1 (de) 2011-08-03
ATE518880T1 (de) 2011-08-15
CZ2003726A3 (cs) 2003-09-17
RU2312143C2 (ru) 2007-12-10
US20120214206A1 (en) 2012-08-23
AU9385501A (en) 2002-03-26
KR20080059684A (ko) 2008-06-30
JP2004508065A (ja) 2004-03-18
KR20030055265A (ko) 2003-07-02
US9370564B2 (en) 2016-06-21
EP1188446B1 (de) 2009-08-05
US20050238637A1 (en) 2005-10-27
AU2001293855B2 (en) 2007-04-26
WO2002022169A2 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
ATE438409T1 (de) Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen
JP4629046B2 (ja) 反復配列タンパク質ポリマー活性剤結合体、方法および使用
ATE245697T1 (de) Klonierung und expression eines gens, das bryodin 1 aus bryonia dioica kodiert
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1117401T1 (el) Πρωτεϊνες συντηξης αλβουμινης
ATE420061T1 (de) 13c,15n,2h markierte proteine zur nmr strukturbestimmung und deren herstellung
IL226857A (en) Recombinant proteins that underwent glycosylation at site n correspond to prokaryotes
DE60144145D1 (de) Subtilisin-variante
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
RU2006145670A (ru) Кератинсвязывающие полипептиды
MX2010004687A (es) Derivados de queratina y metodos de hacer los mismos.
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
ATE522541T1 (de) Bakterielle adhäsine konformere
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
IL206157A (en) Pancreatic elastase protein of type 1, a nucleic acid molecule encoded by a protein
ATE311899T1 (de) Mittel zur verbesserung der immunantwort
PT789764E (pt) Nova familia de inibidores de protease e outras substancias biologicas activas
WO2001025267A3 (en) Improved ricin-like toxins for treatment of cancer
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
AR006150A1 (es) Proteina de via complementaria natural modificada capaz de formar una convertasa c3 resistente a la regulacion descendente, secuencias de adn quecodifican dicha proteina, usos de dicha proteina y composiciones que la contienen
WO2010064132A8 (en) Mutants of staphylokinase carrying amino and carboxy-terminal extensions for polyethylene glycol conjugation
PL341668A1 (en) Composition for oxidatingly dyeing creatine fibre and dyeing method employing such composition
BR0308180A (pt) protéinas de superfìcie de leptospira
WO2005058944A3 (en) Immunogenic peptides fragments of xage-1
AU2001251410A1 (en) 12303, a novel human twik molecule and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1188446

Country of ref document: EP